H.R. 8918: Bioindustrial Infrastructure for Open Scale-up, Commercialization, and Accelerated Launch Ecosystems Act

This bill, titled the "Bioindustrial Infrastructure for Open Scale-up, Commercialization, and Accelerated Launch Ecosystems Act," aims to establish technology maturation facilities specifically for the bioindustrial sector, which focuses on the production of bio-based chemicals, fuels, and materials using biological processes. The bill includes several key elements:

Key Definitions

• Bioindustrial Sector: Industries involved in producing bio-based products through biological and biochemical processes.
• Eligible Entities: Public and private foundations, nonprofit organizations, and institutions of higher education that are incorporated and primarily operate in the United States.
• Facilities: Technology maturation facilities set up under the bill.
• Feedstock: Raw materials used to produce biofuels and bio-based products, such as agricultural byproducts and waste oils.
• Open Access: Ensuring access to resources without intellectual property barriers.
• Technology Maturation: The development and scaling of technologies for commercial use.

Purpose of the Bill

The primary purpose is to position the United States as a leader in bioindustrial innovation by establishing three or more regional, nonprofit, open-access facilities that can support a variety of innovative projects using advanced technologies. These facilities will also aim to enhance commercialization efforts and facilitate technology transfer in alignment with the Department of Energy and the Department of Defense programs.

Facility Establishment and Operation

The bill authorizes the Secretary of Commerce to establish at least three regional technology maturation facilities that will:

• Support various bioindustrial processes.
• Utilize advanced technologies and equipment.
• Work with selected eligible entities through competitive grants for their design, construction, and operation.

The Secretary is also required to submit implementation plans to Congress detailing the criteria for site selection, funding methodologies, outreach strategies, and careful coordination with other federal agencies.

Funding and Use of Funds

The bill authorizes significant appropriations, totaling:

• $345 million for the fiscal years 2026 through 2028.
• $117 million for the fiscal years 2029 through 2030.

Funds are to be used for construction, procurement of equipment, and initial operating expenses of the facilities, with strict deadlines for expenditure based on the facility's existing infrastructure.

Goals and Activities of the Facilities

Each facility is intended to:

• Advance technological innovations in bioindustrial processes.
• Support national security by enhancing biotechnological competencies.
• Boost economic growth and job creation within the U.S.
• Establish secure data-sharing infrastructures.

Oversight and Coordination

The Secretary shall oversee the facilities’ design and construction and establish partnerships with various stakeholders, including federal agencies, educational institutions, and private sector entities. The goal is to ensure effective utilization of resources and equitable access to facilities, especially for rural communities.

Intellectual Property and Data Sharing

Intellectual property created by federal employees in the facilities will be in the public domain, while that created by others will be protected under existing laws. The facilities are expected to facilitate data sharing across government and industry sectors.

Reporting Requirements

The Secretary is required to provide annual reports to Congress, detailing the progress of the facilities, metrics on usage, jobs created, and financial activity, along with any obstacles encountered during operations.

Duration and Future Operations

The authority to establish and operate facilities under this act is set to expire ten years after the enactment, although successful facilities may continue to operate under supervision.

Relevant Companies

• DOW - Dow Inc. operates in the chemical sector and could benefit from advancements in bioindustrial processes and technologies, enhancing its capabilities in producing sustainable materials.
• DNA - Ginkgo Bioworks focuses on the development of synthetic biology technologies and may find opportunities for collaboration in the maturation facilities established by this bill.
• AMRS - Amyris, Inc. is involved in the bio-based materials sector and could leverage the new technology maturation facilities to scale its production processes.